C2230, a preferential use- and state-dependent CaV2.2 channel blocker, mitigates pain behaviors across multiple pain models.
Tang C, Gomez K, Chen Y, Allen HN, Hestehave S, Rodríguez-Palma EJ, Loya-Lopez S, Calderon-Rivera A, Duran P, Nelson TS, Kanumuri SRR, Shah B, Panigrahi NR, Perez-Miller S, Schackmuth MK, Ruparel S, Patwardhan A, Price TJ, Arora PS, Sharma RK, Sharma A, Yu J, Korczeniewska OA, Khanna R.
Tang C, et al. Among authors: ruparel s.
J Clin Invest. 2024 Dec 10:e177429. doi: 10.1172/JCI177429. Online ahead of print.
J Clin Invest. 2024.
PMID: 39656529
Free article.